Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 11/20 | 0.41 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.34 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.33 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7881907 | 0.92 | KMT2A (0.44) | KMT2AMEN1RXFP1ARPLG | |
| SCHEMBL7873484 | 0.89 | KMT2A (0.42) | KMT2AMEN1RXFP1ARPLG | |
| SCHEMBL7879907 | 0.85 | RHEB (0.31) | KMT2AMEN1AR | |
| SCHEMBL7880987 | 0.83 | KMT2A (0.41) | KMT2AMEN1RXFP1ARPLG | |
| SCHEMBL7879507 | 0.83 | RHEB (0.32) | AR | |
| SCHEMBL7881867 | 0.81 | KMT2A (0.43) | KMT2AMEN1RXFP1ARPLG | |
| SCHEMBL7881311 | 0.81 | AR (0.39) | KMT2AMEN1RXFP1ARFLT3 | |
| SCHEMBL7881777 | 0.81 | KMT2A (0.41) | KMT2AMEN1RXFP1PLGPLAU | |
| SCHEMBL7873705 | 0.80 | MEN1 (0.46) | KMT2AMEN1RXFP1PLGPLAU | |
| SCHEMBL7879724 | 0.80 | KMT2A (0.35) | KMT2AMEN1RXFP1ARPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6248772-B1 | HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6169107-B1 | USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS | SUMITOMO PHARMACEUTICAL CO., LTD. (JP) | 2001-01-02 | — | — | US | disclosed |
| EP-0708091-A2 | Indoloylguanidine derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1996-04-24 | — | — | EP | disclosed |